Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.35 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6954344 | 1.00 | GRIA1 (0.35) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL6702567 | 1.00 | GRIA1 (0.35) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL6702564 | 1.00 | GRIA1 (0.35) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL6702566 | 1.00 | GRIA1 (0.35) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL6692310 | 0.87 | GRIA1 (0.36) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL6692306 | 0.87 | GRIA1 (0.36) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL6692314 | 0.87 | GRIA1 (0.36) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL6960039 | 0.87 | GRIA1 (0.36) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL6960035 | 0.87 | GRIA1 (0.36) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL6694832 | 0.81 | SMN1; SMN2 (0.41) | GRIA1GRIA2GRIA3GRIA4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1056742-B1 | ANTI-VIRAL PYRIMIDINE DERIVATIVES | TULARIK INC (US) | 2003-07-23 | — | — | EP | disclosed |
| US-6528513-B2 | Viricides; especially cytomegalo virus | TULARIK INC | 2003-03-04 | — | — | US | disclosed |
| US-20010018436-A1 | Pyrimidine derivatives | TULARIK INC. | 2001-08-30 | — | — | US | disclosed |
| US-6200977-B1 | USEFUL IN TREATING AND SUPPRESSING HUMAN CYTOMEGALOVIRUS | TULARIK INC. | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018436-A1 | Pyrimidine derivatives | TYMP, TYMS, UMPS | GRIA1 3400/4885GRIA2 3715/4885GRIA3 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.